Pacira Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript
Hi. Good morning. I'm Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to our 22nd Annual Healthcare Conference. For our next session. We have the Pacira team with us, so the CEO, David Stack; as well as the CFO, Charles Reinhart. So welcome, gentlemen, and I'll hand it over to David to just to give us a brief overview of the company.
[We'll get] the questions, and for those listening in on the portal, you do have the options to submit questions. I think it's at the bottom of your screen. So, David?
Good morning, Serge, and thanks for the opportunity. Through Q1, I think we're -- the easiest thing to say, I guess, is that we're on plan. The marketplace remains relatively soft for soft-tissue procedures. In the hard-tissue procedure in the orthopedic space, we would echo what folks would have heard from many of the device companies that knees and hips are growing. The rest of [orthopedics] looks a lot
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |